Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model

Stroke

Volumn 43, Issue 2, 2012, Pages 499-506

  Kasahara, Yukiko ^a   Nakagomi, Takayuki ^b   Matsuyama, Tomohiro ^b   Stern, David ^c   Taguchi, Akihiko ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

antiplatelet drugs; brain ischemia; ICH; murine model; thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CYCLIC AMP; FIBRINOLYTIC AGENT; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HEMORRHAGE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INDUCTION; FIBRINOLYTIC THERAPY; IMMUNOHISTOLOGY; MICROVASCULATURE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ASPIRIN; BRAIN; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; IMMUNOHISTOCHEMISTRY; ISCHEMIC ATTACK, TRANSIENT; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; REPERFUSION INJURY; STROKE; TETRAZOLES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84856506320     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.635417     Document Type: Article

References (54)

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet. 2004; 363:768-774.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Meschia JF, Brott TG. New insights on thrombolytic treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001;1:19-25.
4. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006;37: 556-561. (Pubitemid 43732026)
5. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32: 438-441. (Pubitemid 32155231)
6. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003;16: 183-190. (Pubitemid 36928607)
7. Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41: 288-294.
8. Grotta JC, Welch KM, Fagan SC, Lu M, Frankel MR, Brott T, et al. Clinical deterioration following improvement in the NINDS rtPA stroke trial. Stroke. 2001;32:661-668.
9. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65:607-611. (Pubitemid 351679654)
10. Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36:1452-1456. (Pubitemid 40967511)
11. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59: 862-867.
12. Fassbender K, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30:2101-2104. (Pubitemid 29473255)
13. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006;37:1798-1804. (Pubitemid 44297732)
14. Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB. A randomised controlled trial of antiplatelet therapy in combination with rtPA thrombolysis in ischemic stroke: rationale and design of the ARTIS-trial. Trials. 2010;11:51.
15. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959-968.
16. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;1:CD008076.
17. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing pad with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710-713. (Pubitemid 37254796)
18. Kasahara Y, Taguchi A, Uno H, Nakano A, Nakagomi T, Hirose H, et al. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res. 2010;1340:70-80.
19. Matsushita K, Matsuyama T, Nishimura H, Takaoka T, Kuwabara K, Tsukamoto Y, et al. Marked, sustained expression of a novel 150-kDa oxygen-regulated stress protein, in severely ischemic mouse neurons. Brain Res Mol Brain Res. 1998;60:98-106. (Pubitemid 28433199)
20. Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura-Matsuoka E, et al. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke. 2011;42:2571-2577.
21. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, Imaizumi T, et al. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung. 2007;57:185-191. (Pubitemid 46724187)
22. Ito H, Hashimoto A, Matsumoto Y, Yao H, Miyakoda G. Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J Cereb Blood Flow Metab. 2010;30: 343-351.
23. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836. (Pubitemid 34204013)
24. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 2009; 29:715-725.
25. Hata R, Mies G, Wiessner C, Fritze K, Hesselbarth D, Brinker G, et al. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab. 1998;18:367-375. (Pubitemid 28166511)
26. Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol. 2006;26:1099-1111. (Pubitemid 44924033)
27. Taguchi A, Zhu P, Cao F, Kikuchi-Taura A, Kasahara Y, Stern DM, et al. Reduced ischemic brain injury by partial rejuvenation of bone marrow cells in aged rats. J Cereb Blood Flow Metab. 2011;31:855-867.
28. Aronowski J, Strong R, Shirzadi A, Grotta JC. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke. 2003;34:1246-1251. (Pubitemid 36547523)
29. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: Asymptomatic or symptomatic? Stroke. 2001;32:1330-1335. (Pubitemid 32530418)
30. Clark WM, Madden KP, Lyden PD, Zivin JA. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke. 1991;22:872-876.
31. Park S, DiMaio TA, Scheef EA, Sorenson CM, Sheibani N. PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. Am J Physiol Cell Physiol. 2010;299:C1468-1484.
32. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27: 697-709. (Pubitemid 46474608)
33. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533-1540. (Pubitemid 38056279)
34. Duran-Vilaregut J, Del Valle J, Manich G, Camins A, Pallas M, Vilaplana J, et al. Role of MMP-9 in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease. Neuropathol Appl Neurobiol. 2010;37:525-537.
35. Vivien D, Buisson A. Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab. 2000;20:755-764. (Pubitemid 30317049)
36. Kahles T, Foerch C, Sitzer M, Schroeter M, Steinmetz H, Rami A, et al. Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent. Vascul Pharmacol. 2005;43: 254-259. (Pubitemid 41586212)
37. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36:1954-1959. (Pubitemid 41266533)
38. Taguchi A, Kasahara Y, Nakagomi T, Stern DM, Fukunaga M, Ishikawa M, et al. A reproducible and simple model of permanent cerebral ischemia in CB-17 and SCID mice. J Exp Stroke Transl Med. 2010;3:28-33.
39. Valiente RA, de Miranda-Alves MA, Silva GS, Gomes DL, Brucki SM, Rocha MS, et al. Clinical features associated with early hospital arrival after acute intracerebral hemorrhage: challenges for new trials. Cerebrovasc Dis. 2008;26:404-408.
40. Hanggi D, Steiger HJ. Spontaneous intracerebral haemorrhage in adults: A literature overview. Acta Neurochir (Wien). 2008;150:371-379; discussion 379.
41. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke. 2008;39:3316-3322.
42. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
43. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005; 6:3-11. (Pubitemid 43263084)
44. Lapchak PA, Han MK. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res. 2009;1303:144-150.
45. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol. 2008;255:875-880.
46. Yagi K, Kitazato KT, Uno M, Tada Y, Kinouchi T, Shimada K, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke. 2009; 40:626-631.
47. Bauer AT, Burgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab. 2010;30:837-848.
48. Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, et al. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPSadministrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem. 2008;103:54-66.
49. Ishizaki T, Chiba H, Kojima T, Fujibe M, Soma T, Miyajima H, et al. Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and-independent pathways. Exp Cell Res. 2003;290:275-288. (Pubitemid 37272172)
50. Yan SF, Ogawa S, Stern DM, Pinsky DJ. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int. 1997;51:419-425. (Pubitemid 27088153)
51. Torii H, Kubota H, Ishihara H, Suzuki M. Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res. 2007; 55:104-110. (Pubitemid 46186035)
52. Lim JH, Woo JS, Shin YW. Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2-and P38 MAPKdependent pathways. Korean J Intern Med. 2009;24:113-122.
53. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, Kato S, Unemi F, Kimura Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57: 617-623. (Pubitemid 20110427)
54. Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K. Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb. 2010;17:503-509.